Click here to get full coverage on Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year?  Yahoo Finance

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $APGE Given $95 Price Target - Quiver Quantitative

New Analyst Forecast: $APGE Given $95 Price Target  Quiver Quantitative

New Analyst Forecast: $APGE Given $95 Price Target - Quiver Quantitative

Click here to get full coverage on Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq

Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation  Nasdaq

Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High - What's Next? - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High - What's Next?  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High - What's Next? - MarketBeat

Click here to get full coverage on Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Finviz

Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth  Finviz

Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Finviz

Click here to get full coverage on Assessing Apogee Therapeutics (APGE) Valuation After Stephens Highlights APG777’s Potential in Atopic Dermatitis - simplywall.st

Assessing Apogee Therapeutics (APGE) Valuation After Stephens Highlights APG777’s Potential in Atopic Dermatitis  simplywall.st

Assessing Apogee Therapeutics (APGE) Valuation After Stephens Highlights APG777’s Potential in Atopic Dermatitis - simplywall.st

Click here to get full coverage on How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily

How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing  Stock Traders Daily

How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat

Click here to get full coverage on The Bull Case For Apogee Therapeutics (APGE) Could Change Following Stephens’ Focus On APG777 Versus Dupixent - simplywall.st

The Bull Case For Apogee Therapeutics (APGE) Could Change Following Stephens’ Focus On APG777 Versus Dupixent  simplywall.st

The Bull Case For Apogee Therapeutics (APGE) Could Change Following Stephens’ Focus On APG777 Versus Dupixent - simplywall.st

Click here to get full coverage on Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade - Nasdaq

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade  Nasdaq

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade - Nasdaq

Click here to get full coverage on BTIG Maintains a Buy on Apogee Therapeutics (APGE) - Yahoo Finance

BTIG Maintains a Buy on Apogee Therapeutics (APGE)  Yahoo Finance

BTIG Maintains a Buy on Apogee Therapeutics (APGE) - Yahoo Finance

Click here to get full coverage on $APGE stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$APGE stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$APGE stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat

Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock  MarketBeat

Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat

Click here to get full coverage on RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - Yahoo Finance

RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating  Yahoo Finance

RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - Yahoo Finance

Click here to get full coverage on Insider Sale: Chief Executive Officer of $APGE Sells 3,340 Shares - Quiver Quantitative

Insider Sale: Chief Executive Officer of $APGE Sells 3,340 Shares  Quiver Quantitative

Insider Sale: Chief Executive Officer of $APGE Sells 3,340 Shares - Quiver Quantitative

Click here to get full coverage on BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - Yahoo Finance

BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis  Yahoo Finance

BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - Yahoo Finance

Click here to get full coverage on Why Apogee Therapeutics (APGE) Is Up 19.7% After Strong APG333 Trial Data and Cash Infusion - Yahoo Finance

Why Apogee Therapeutics (APGE) Is Up 19.7% After Strong APG333 Trial Data and Cash Infusion  Yahoo Finance

Why Apogee Therapeutics (APGE) Is Up 19.7% After Strong APG333 Trial Data and Cash Infusion - Yahoo Finance

Click here to get full coverage on Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - Yahoo Finance

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors  Yahoo Finance

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - Yahoo Finance

Click here to get full coverage on $300M Offering: Apogee Therapeutics Prices 6.95M Shares; Includes Pre-funded Warrants Exercisable Immediately - Stock Titan

$300M Offering: Apogee Therapeutics Prices 6.95M Shares; Includes Pre-funded Warrants Exercisable Immediately  Stock Titan

$300M Offering: Apogee Therapeutics Prices 6.95M Shares; Includes Pre-funded Warrants Exercisable Immediately - Stock Titan

Click here to get full coverage on Noteworthy Wednesday Option Activity: MRNA, APGE, EU - Nasdaq

Noteworthy Wednesday Option Activity: MRNA, APGE, EU  Nasdaq

Noteworthy Wednesday Option Activity: MRNA, APGE, EU - Nasdaq

Click here to get full coverage on Apogee Therapeutics initiated with an overweight at Stephens - MSN

Apogee Therapeutics initiated with an overweight at Stephens  MSN

Apogee Therapeutics initiated with an overweight at Stephens - MSN

Click here to get full coverage on 15% Overallotment Option — Apogee Therapeutics Commences Public Offering to Fund Trials - Stock Titan

15% Overallotment Option — Apogee Therapeutics Commences Public Offering to Fund Trials  Stock Titan

15% Overallotment Option — Apogee Therapeutics Commences Public Offering to Fund Trials - Stock Titan

Click here to get full coverage on Stempoint Capital LP Makes New Investment in Apogee Therapeutics Inc. $APGE - MarketBeat

Stempoint Capital LP Makes New Investment in Apogee Therapeutics Inc. $APGE  MarketBeat

Stempoint Capital LP Makes New Investment in Apogee Therapeutics Inc. $APGE - MarketBeat

Click here to get full coverage on Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Brokerages  MarketBeat

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) CEO Sells $3,000,400.00 in Stock - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) CEO Sells $3,000,400.00 in Stock  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) CEO Sells $3,000,400.00 in Stock - MarketBeat

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year High - Here's Why - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year High - Here's Why  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year High - Here's Why - MarketBeat

Click here to get full coverage on Schroder Investment Management Group Boosts Stock Position in Apogee Therapeutics Inc. $APGE - MarketBeat

Schroder Investment Management Group Boosts Stock Position in Apogee Therapeutics Inc. $APGE  MarketBeat

Schroder Investment Management Group Boosts Stock Position in Apogee Therapeutics Inc. $APGE - MarketBeat

Click here to get full coverage on Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Yahoo Finance

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)  Yahoo Finance

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Yahoo Finance

Click here to get full coverage on Craig-Hallum Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq

Craig-Hallum Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation  Nasdaq

Craig-Hallum Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Downgraded by Wall Street Zen to "Sell" - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Downgraded by Wall Street Zen to "Sell"  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Downgraded by Wall Street Zen to "Sell" - MarketBeat

Click here to get full coverage on Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade - Zacks Investment Research

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade  Zacks Investment Research

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade - Zacks Investment Research

Click here to get full coverage on BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com

BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook  Investing.com

BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com

Click here to get full coverage on Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 - Stock Titan

Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333  Stock Titan

Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 - Stock Titan

Click here to get full coverage on $345M Raised — Apogee Therapeutics Closes Offering of 8.05M Shares Including Pre-Funded Warrants - Stock Titan

$345M Raised — Apogee Therapeutics Closes Offering of 8.05M Shares Including Pre-Funded Warrants  Stock Titan

$345M Raised — Apogee Therapeutics Closes Offering of 8.05M Shares Including Pre-Funded Warrants - Stock Titan

Click here to get full coverage on Apogee Therapeutics (APGE): Assessing Valuation Following $300 Million Equity Raise - Yahoo Finance

Apogee Therapeutics (APGE): Assessing Valuation Following $300 Million Equity Raise  Yahoo Finance

Apogee Therapeutics (APGE): Assessing Valuation Following $300 Million Equity Raise - Yahoo Finance

Click here to get full coverage on Apogee Therapeutics (NASDAQ:APGE) Posts Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Posts Earnings Results, Beats Estimates By $0.03 EPS  MarketBeat

Apogee Therapeutics (NASDAQ:APGE) Posts Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Click here to get full coverage on Apogee Therapeutics (NASDAQ: APGE) to join five fireside chats; webcast available - Stock Titan

Apogee Therapeutics (NASDAQ: APGE) to join five fireside chats; webcast available  Stock Titan

Apogee Therapeutics (NASDAQ: APGE) to join five fireside chats; webcast available - Stock Titan

Click here to get full coverage on Craig-Hallum Sticks to Its Buy Rating for Apogee Therapeutics (APGE) - The Globe and Mail

Craig-Hallum Sticks to Its Buy Rating for Apogee Therapeutics (APGE)  The Globe and Mail

Craig-Hallum Sticks to Its Buy Rating for Apogee Therapeutics (APGE) - The Globe and Mail

Click here to get full coverage on CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89 - 富途牛牛

CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89  富途牛牛

CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89 - 富途牛牛

Click here to get full coverage on Apogee Therapeutics’ Stock Surge: Is It Time To Jump In? - timothysykes.com

Apogee Therapeutics’ Stock Surge: Is It Time To Jump In?  timothysykes.com

Apogee Therapeutics’ Stock Surge: Is It Time To Jump In? - timothysykes.com

Click here to get full coverage on Apogee falls after results from atopic dermatitis trial (APGE:NASDAQ) - Seeking Alpha

Apogee falls after results from atopic dermatitis trial (APGE:NASDAQ)  Seeking Alpha

Apogee falls after results from atopic dermatitis trial (APGE:NASDAQ) - Seeking Alpha

Click here to get full coverage on Apogee Therapeutics (APGE) Stock Drops Despite Trial Success - GuruFocus

Apogee Therapeutics (APGE) Stock Drops Despite Trial Success  GuruFocus

Apogee Therapeutics (APGE) Stock Drops Despite Trial Success - GuruFocus

Click here to get full coverage on Why Apogee Therapeutics Stock Triumphed on Thursday - The Motley Fool

Why Apogee Therapeutics Stock Triumphed on Thursday  The Motley Fool

Why Apogee Therapeutics Stock Triumphed on Thursday - The Motley Fool

Click here to get full coverage on Insider Sell: Jane Henderson Sells 1,500 Shares of Apogee Therap - GuruFocus

Insider Sell: Jane Henderson Sells 1,500 Shares of Apogee Therap  GuruFocus

Insider Sell: Jane Henderson Sells 1,500 Shares of Apogee Therap - GuruFocus

Click here to get full coverage on Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Finviz

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)  Finviz

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Finviz

Click here to get full coverage on Henderson Jane, CFO of Apogee Therapeutics, sells $130k in stock - Investing.com

Henderson Jane, CFO of Apogee Therapeutics, sells $130k in stock  Investing.com

Henderson Jane, CFO of Apogee Therapeutics, sells $130k in stock - Investing.com

Click here to get full coverage on Apogee Therapeutics launches common stock public offering - Investing.com

Apogee Therapeutics launches common stock public offering  Investing.com

Apogee Therapeutics launches common stock public offering - Investing.com

Click here to get full coverage on Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody  GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - GlobeNewswire

Click here to get full coverage on CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus

CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE)  GuruFocus

CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus

Click here to get full coverage on Biotech Innovator Apogee Therapeutics Featured at Upcoming Stifel 2025 Immunology Conference - Stock Titan

Biotech Innovator Apogee Therapeutics Featured at Upcoming Stifel 2025 Immunology Conference  Stock Titan

Biotech Innovator Apogee Therapeutics Featured at Upcoming Stifel 2025 Immunology Conference - Stock Titan

Click here to get full coverage on Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth - Yahoo Finance

Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth  Yahoo Finance

Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth - Yahoo Finance

Click here to get full coverage on Apogee Therapeutics Closes $345 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Apogee Therapeutics Closes $345 Million Public Offering of Common Stock and Pre-Funded Warrants  Quiver Quantitative

Apogee Therapeutics Closes $345 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Click here to get full coverage on Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering  GlobeNewswire

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire

Click here to get full coverage on Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session  Benzinga

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Click here to get full coverage on Is APGE stock supported by strong fundamentals - Earnings Growth Summary & Real-Time Market Sentiment Alerts - Bölüm Sonu Canavarı

Is APGE stock supported by strong fundamentals - Earnings Growth Summary & Real-Time Market Sentiment Alerts  Bölüm Sonu Canavarı

Is APGE stock supported by strong fundamentals - Earnings Growth Summary & Real-Time Market Sentiment Alerts - Bölüm Sonu Canavarı

Click here to get full coverage on Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025 - simplywall.st

Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025  simplywall.st

Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025 - simplywall.st

Click here to get full coverage on Apogee Therapeutics Updates Pipeline Progress and Financial Results, Anticipates Four Key Clinical Data Readouts in 2026 - Quiver Quantitative

Apogee Therapeutics Updates Pipeline Progress and Financial Results, Anticipates Four Key Clinical Data Readouts in 2026  Quiver Quantitative

Apogee Therapeutics Updates Pipeline Progress and Financial Results, Anticipates Four Key Clinical Data Readouts in 2026 - Quiver Quantitative

Click here to get full coverage on Apogee Therapeutics stock initiated at Outperform by RBC Capital - Investing.com

Apogee Therapeutics stock initiated at Outperform by RBC Capital  Investing.com

Apogee Therapeutics stock initiated at Outperform by RBC Capital - Investing.com

Click here to get full coverage on Apogee Therapeutics stock initiated with Buy rating at Craig-Hallum - Investing.com

Apogee Therapeutics stock initiated with Buy rating at Craig-Hallum  Investing.com

Apogee Therapeutics stock initiated with Buy rating at Craig-Hallum - Investing.com

Click here to get full coverage on Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data - Investing.com

Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data  Investing.com

Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data - Investing.com

Click here to get full coverage on Apogee Therapeutics Announces Positive Phase 1 Results - TipRanks

Apogee Therapeutics Announces Positive Phase 1 Results  TipRanks

Apogee Therapeutics Announces Positive Phase 1 Results - TipRanks

Click here to get full coverage on Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE) - Seeking Alpha

Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE)  Seeking Alpha

Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE) - Seeking Alpha

Click here to get full coverage on Apogee Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Apogee Therapeutics Reports Positive Phase 2 Trial Results  TipRanks

Apogee Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Click here to get full coverage on Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - Yahoo Finance

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results  Yahoo Finance

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - Yahoo Finance

Click here to get full coverage on How This Small Biotech Is Looking To Take On Sanofi's Cash Cow - Investor's Business Daily

How This Small Biotech Is Looking To Take On Sanofi's Cash Cow  Investor's Business Daily

How This Small Biotech Is Looking To Take On Sanofi's Cash Cow - Investor's Business Daily

Click here to get full coverage on Can APGE stock reach $100 price target - 2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - moha.gov.vn

Can APGE stock reach $100 price target - 2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas  moha.gov.vn

Can APGE stock reach $100 price target - 2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - moha.gov.vn

Click here to get full coverage on Apogee Therapeutics CEO Henderson sells $3.0 million in stock - Investing.com

Apogee Therapeutics CEO Henderson sells $3.0 million in stock  Investing.com

APGE

Price Chart

Key Statistics

Technicals

About APGE

Latest News

Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Yahoo Finance

New Analyst Forecast: $APGE Given $95 Price Target - Quiver Quantitative

Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq

Advanced Charts

Top Gainers

Top Losers